相关实验视频

Updated: Jan 11, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

冠状瘤的质子束疗法:系统性审查和元分析

Meng Dong¹, Yuan Liu¹, Juan Bai²

¹Department of Interventional Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province 610036, China.

Critical reviews in oncology/hematology

|November 12, 2025

概括

质子束疗法 (PBT) 提供了一种安全有效的局部治疗策略,用于瘤,显示了高局部控制率和整体存活率. 该疗法显示可接受的毒性概况,使其成为胆瘤患者的可行选择.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
医学物理医学物理

背景情况:

胆瘤是一种罕见的骨瘤,需要有效的治疗策略.
质子束疗法 (PBT) 是一种先进的辐射技术,对局部瘤具有潜在的益处.

研究的目的:

系统地评估质子束疗法 (PBT) 在瘤治疗中的有效性和安全性.
分析瘤患者的生存结果和与PBT相关的毒性.

主要方法:

在主要数据库 (PubMed,Embase,Web of Science,Cochrane Library) 进行了全面的文献搜索,截至2025年2月25日.
包括11项报告561名接受PBT治疗的瘤患者的研究.
提取和分析了关于生存结果和毒性的数据.

主要成果:

质子束疗法显示出高局部控制 (LC) 率,在7年达到71%;整体存活率在7年达到80%.
管理的总剂量的中位数是74 Gy (RBE).
急性和晚期毒性主要是1级和2级,表明可接受的安全性.

结论:

质子束疗法是一种临床适用和安全的局部治疗心脏瘤.
在心脏瘤局部控制和整体存活率方面,PBT显示了令人鼓舞的疗效.
对于心脏瘤的PBT观察到的毒性概况是可以接受的.

关键词:

一个叫做chordoma的小组.进行元分析分析.颗粒颗粒颗粒的粒子质子疗法是一种质子疗法.系统性审查系统性审查

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...